This study aimed to evaluate the predictive utility of serum aminotransferases (GOT and GPT) for non-alcoholic fatty liver disease in the context of metabolic risk factors, with an emphasis on early identification before irreversible liver damage occurs. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.